Strides Arcolab up 5%, gets US FDA nod for Italian facility

Strides is developing a portfolio of liquids and semi-solids products for the US and EU markets. Currently it has over 12 products at various stages of developments and approvals. The drug maker already sells semi-solids in the UK market.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead Travelcafe
moneycontrol.com

Home » News » Buzzing Stocks

Sep 19, 2013, 08.14 AM | Source: Moneycontrol.com

Strides Arcolab up 5%, gets US FDA nod for Italian facility

Strides is developing a portfolio of liquids and semi-solids products for the US and EU markets. Currently it has over 12 products at various stages of developments and approvals. The drug maker already sells semi-solids in the UK market.

Like this story, share it with millions of investors on M3

Strides Arcolab up 5%, gets US FDA nod for Italian facility

Strides is developing a portfolio of liquids and semi-solids products for the US and EU markets. Currently it has over 12 products at various stages of developments and approvals. The drug maker already sells semi-solids in the UK market.

Post Your Comments

Share Cancel

Moneycontrol Bureau

Shares of Strides Arcolab jumped 5 percent intraday on Wednesday. The drug maker has received United States Food and Drug Administration (US FDA) approval for its semi-solid and ointment facility in Milan, Italy. 

"The company is expecting its first approval of a niche semisolid product by Q1 FY2014, " it said in a filling to the BSE.

Strides is developing a portfolio of liquids and semi-solids products for the US and EU markets. Currently it has over 12 products at various stages of developments and approvals. The drug maker already sells semi-solids in the UK market.

Don't miss: Jewellery stocks rally 2-7% on import duty hike

Meanwhile, in a related development Mylan believes that the warning letter to Agila will not have any material impact to its overall combined financial assumptions. It expects Agila and Mylan to cumulatively resolve the issue. Mylan expects to close the deal by Q4CY13 as per plans since it has got all the major approvals from regulatory bodies.

Strides Arcolab closed at Rs 878.65, up Rs 31.65, or 3.74 percent on the BSE in a volatile market.

(Posted by Nasrin Sultana)

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
Strides Arcolab up 5%, gets US FDA nod for Italian facility

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login